Eli Lilly and Company (LLY)vsPalisade Bio Inc (PALI)
LLY
Eli Lilly and Company
$1,289.42
+0.50%
HEALTHCARE · Cap: $1.12T
PALI
Palisade Bio Inc
$1.19
-0.83%
HEALTHCARE · Cap: $231.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 15933101% more annual revenue ($79.67B vs $500,000). LLY leads profitability with a 33.5% profit margin vs 0.0%. PALI trades at a lower P/E of 2.2x. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PALI
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+55.0%
Fair Value
$3.87
Current Price
$1.19
$2.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Attractively priced relative to earnings
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.9x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : PALI
The strongest argument for PALI centers on P/E Ratio, Altman Z-Score, Price/Book.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PALI
The primary concerns for PALI are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while PALI is a value play — different risk/reward profiles.
PALI carries more volatility with a beta of 1.62 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 21/100), backed by strong 33.5% margins and 47.7% revenue growth. PALI offers better value entry with a 55.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Palisade Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company is headquartered in Carlsbad, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?